DK1676847T3 - Polymorfe former af rifaximin som antibiotika - Google Patents

Polymorfe former af rifaximin som antibiotika

Info

Publication number
DK1676847T3
DK1676847T3 DK06004219T DK06004219T DK1676847T3 DK 1676847 T3 DK1676847 T3 DK 1676847T3 DK 06004219 T DK06004219 T DK 06004219T DK 06004219 T DK06004219 T DK 06004219T DK 1676847 T3 DK1676847 T3 DK 1676847T3
Authority
DK
Denmark
Prior art keywords
rifaximin
antibiotics
polymorphic forms
polymorphic
forms
Prior art date
Application number
DK06004219T
Other languages
Danish (da)
English (en)
Inventor
Giuseppe C Viscomi
Manuela Campana
Dario Braga
Donatella Confortini
Vincenzo Cannata
Denis Severini
Paolo Righi
Goffredo Rosini
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1676847(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Application granted granted Critical
Publication of DK1676847T3 publication Critical patent/DK1676847T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • HELECTRICITY
    • H05ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05BELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00Heating by electric, magnetic or electromagnetic fields
    • H05B6/02Induction heating
    • H05B6/10Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12Cooking devices
    • H05B6/1209Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • HELECTRICITY
    • H05ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05BELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00Heating by electric, magnetic or electromagnetic fields
    • H05B6/02Induction heating
    • H05B6/10Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12Cooking devices
    • H05B6/1209Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
DK06004219T 2003-11-07 2004-03-09 Polymorfe former af rifaximin som antibiotika DK1676847T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e

Publications (1)

Publication Number Publication Date
DK1676847T3 true DK1676847T3 (da) 2009-05-11

Family

ID=33187382

Family Applications (3)

Application Number Title Priority Date Filing Date
DK06004219T DK1676847T3 (da) 2003-11-07 2004-03-09 Polymorfe former af rifaximin som antibiotika
DK04005541T DK1557421T3 (da) 2003-11-07 2004-03-09 Polymorfe form af rifaximin som antibiotikum
DK06004220T DK1676848T3 (da) 2003-11-07 2004-03-09 Polymorfe former af rifaximin som antibiotika

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK04005541T DK1557421T3 (da) 2003-11-07 2004-03-09 Polymorfe form af rifaximin som antibiotikum
DK06004220T DK1676848T3 (da) 2003-11-07 2004-03-09 Polymorfe former af rifaximin som antibiotika

Country Status (37)

Country Link
US (5) US7045620B2 (fr)
EP (6) EP1676848B1 (fr)
JP (5) JP2005139161A (fr)
KR (4) KR20050043589A (fr)
CN (4) CN1613858A (fr)
AR (3) AR043547A1 (fr)
AT (3) ATE421965T1 (fr)
AU (2) AU2004200964A1 (fr)
BR (2) BRPI0402382A (fr)
CA (2) CA2460384A1 (fr)
CL (1) CL2004000498A1 (fr)
CO (1) CO5560083A1 (fr)
CY (3) CY1108017T1 (fr)
DE (4) DE602004019298D1 (fr)
DK (3) DK1676847T3 (fr)
ES (3) ES2244364T3 (fr)
HR (2) HRP20040265A2 (fr)
IL (2) IL160798A0 (fr)
IT (1) ITMI20032144A1 (fr)
JO (1) JO2470B1 (fr)
MA (1) MA27069A1 (fr)
MD (1) MD3653G8 (fr)
ME (1) ME00424B (fr)
MX (2) MXPA04002353A (fr)
NO (1) NO334950B1 (fr)
NZ (1) NZ531622A (fr)
PL (3) PL1676847T3 (fr)
PT (3) PT1676847E (fr)
RS (4) RS54569B1 (fr)
RU (1) RU2270200C2 (fr)
SI (3) SI1676848T1 (fr)
TN (2) TNSN04044A1 (fr)
TW (1) TWI285107B (fr)
UA (1) UA86384C2 (fr)
WO (1) WO2005044823A2 (fr)
YU (1) YU24804A (fr)
ZA (1) ZA200401948B (fr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
PT1698630E (pt) * 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
EP2054066B1 (fr) 2006-08-02 2015-04-15 Salix Pharmaceuticals, Inc. Procede de traitement de l'enterites causee par l'exposition au rayonnement
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
KR101667534B1 (ko) * 2006-09-22 2016-10-19 씨아이피엘에이 엘티디. 리팍시민
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドLupin Limited リファキシミンの薬剤組成物
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
EP2011486B2 (fr) * 2007-07-06 2015-08-12 Lupin Ltd. Compositions pharmaceutiques de rifaximine
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
UA113275C2 (xx) * 2008-02-25 2017-01-10 ζ-ФОРМА РИФАКСИМІНУ І ЇЇ ЗАСТОСУВАННЯ
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
PT2252148T (pt) * 2008-02-26 2020-01-23 Salix Pharmaceuticals Ltd Métodos de tratamento da síndrome do intestino irritável
WO2009137672A1 (fr) 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Procédés de traitement de maladie intestinale par l’administration d’un nettoyant d’intestin et d’un antibiotique
US8980872B2 (en) 2008-09-26 2015-03-17 Aska Pharmaceutical Co., Ltd. Agent for preventing and/or treating functional gastrointestinal disorder
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
HUE048293T2 (hu) 2008-10-02 2020-07-28 Salix Pharmaceuticals Ltd Eljárások hepatikus enkefalopátia kezelésére
ES2718614T3 (es) 2008-12-10 2019-07-03 Cipla Ltd Complejos de rifaximina
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
BRPI1010028A2 (pt) * 2009-06-02 2019-02-12 Salix Pharmaceuticals, Ltd. métodos de tratamento de encefalopatia hepática
BR112012005627A2 (pt) * 2009-09-13 2017-02-21 Salix Pharmaceuticals Ltd "uso de rifaximina para preparação de um medicamento para tratar síndrome do intestino irritável (ibs)"
MY177151A (en) * 2009-10-27 2020-09-08 Lupin Ltd Solid dispersion of rifaximin
WO2011061748A1 (fr) * 2009-11-19 2011-05-26 Strides Arcolab Limited Prémélange à base de rifaximine
RU2012126084A (ru) 2009-11-23 2013-12-27 Сипла Лимитед Пенная композиция для местного применения
WO2011080691A1 (fr) 2009-12-28 2011-07-07 Silvio Massimo Lavagna Procédés pour la production de rifaximine amorphe
AU2011218129A1 (en) 2010-02-18 2012-08-23 Board Of Regents Of The University Of Texas System Methods for treating infection
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
EA022490B1 (ru) * 2010-06-03 2016-01-29 Саликс Фармасьютикалс, Лтд. Новые формы рифаксимина и их применение
CA2802874A1 (fr) * 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Formes polymorphiques de rifaximine
ES2801678T3 (es) 2010-07-12 2021-01-12 Salix Pharmaceuticals Inc Formulaciones de rifaximina y sus usos
WO2012035544A2 (fr) 2010-09-13 2012-03-22 Sequent Scientific Ltd. Nouvelle forme polymorphe de rifaximine et son procédé de préparation
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (fr) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Procédé de préparation de rifaximine amorphe
WO2012076832A1 (fr) * 2010-12-09 2012-06-14 Cipla Limited Suppositoires contenant de la rifaximine
SG192122A1 (en) * 2011-02-11 2013-08-30 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
WO2012150561A1 (fr) 2011-05-02 2012-11-08 Ranbaxy Laboratories Limited Solvate de diméthylformamide rifaximine
WO2012155981A1 (fr) 2011-05-19 2012-11-22 Friulchem Spa Nouveau procédé pour la synthèse de rifaximine et nouvelle forme pseudo-cristalline de rifaximine obtenue au moyen de celui-ci
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CA2854380A1 (fr) 2011-11-02 2013-05-10 Salix Pharmaceuticals, Ltd. Methodes de traitement du syndrome du colon irritable (ibs) et d'infections associees
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
CA2876737A1 (fr) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Formes polymorphes de rifaximine
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
CN105142636A (zh) 2013-03-15 2015-12-09 意大利阿尔法韦士曼制药公司 用于治疗阴道感染的利福昔明
WO2014140995A2 (fr) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Procédé pour diagnostiquer des infections vaginales
EP2983647B1 (fr) 2013-04-12 2020-09-09 Alfasigma S.p.A. Administration d'ains, compositions, procédés et systèmes associés
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
EP3134415A4 (fr) * 2014-04-19 2017-10-25 Granules India Limited Procédé amélioré pour la préparation de dérivés de la rifamycine
EP3140313B1 (fr) 2014-05-04 2020-02-26 Salix Pharmaceuticals, Inc. Microbiote du syndrome du côlon irritable et utilisations associées
NZ723571A (en) 2014-05-12 2020-02-28 Alfasigma Spa New solvated crystal form of rifaximin, production, compositions and uses thereof
MX381919B (es) * 2014-06-30 2025-03-13 Salix Pharmaceuticals Inc Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (fr) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification de bactérie vaginale
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (fr) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Procédé de préparation de formes cristallines de rifaximine
WO2017162725A1 (fr) 2016-03-24 2017-09-28 Sandoz Ag Composition pharmaceutique contenant de la rifaximine alpha et delta
TR201909029T4 (tr) 2016-03-24 2019-07-22 Sandoz Ag Rifaksimin alfa içeren saklanmaya yönelik kararlı bileşimler.
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
PT3518924T (pt) 2016-09-30 2022-10-27 Salix Pharmaceuticals Inc Formas de dispersão sólidas de rifaximina
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
PL3416627T3 (pl) 2017-04-26 2020-06-01 Sandoz Ag Doustna postać dawkowania zawierająca rifaksyminę w postaci beta
MX386622B (es) 2017-06-26 2025-03-19 Biofer Spa Derivados de pirido-imidazo rifamicina como agente antibacteriano
WO2020128583A1 (fr) * 2018-12-19 2020-06-25 Friulchem S.P.A. Procédé de fabrication d'un comprimé de rifaximine et comprimé de rifaximine
WO2020245214A1 (fr) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Utilisation de méthylnaltrexone et de rifaximine pour le traitement d'une perméabilité intestinale accrue ou de troubles associés
EP4034091A1 (fr) 2019-09-24 2022-08-03 Bausch Health Ireland Limited Formulations liquides de rifaximine
WO2021191312A1 (fr) 2020-03-24 2021-09-30 Bausch Health Ireland Limited Procédés de traitement de la covid-19 avec de la rifaximine
WO2021229480A1 (fr) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorphe de la rifaximine, son procédé de préparation et composition pharmaceutique contenant de la rifaximine
AU2021298178A1 (en) 2020-06-26 2023-02-02 Bausch Health Ireland Limited Targeted release rifaximin compositions
US20230398102A1 (en) 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
CA1215976A (fr) 1984-05-15 1986-12-30 Vincenzo Cannata Nouvelle methode pour la synthese d'imidazorifamycines
IT1199374B (it) * 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
DK0536197T3 (da) * 1990-06-29 1995-11-13 Lepetit Spa Ren, krystallinsk form af rifapentine
WO2001051919A2 (fr) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. Formation, identification et analyse a productivites elevees de formes solides diverses
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
PL361912A1 (en) * 2000-10-31 2004-10-04 Ciba Specialty Chemicals Holding Inc. Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
KR101667534B1 (ko) * 2006-09-22 2016-10-19 씨아이피엘에이 엘티디. 리팍시민
WO2008115572A1 (fr) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Procédés et compositions d'ains
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
EP2011486B2 (fr) 2007-07-06 2015-08-12 Lupin Ltd. Compositions pharmaceutiques de rifaximine
JP5755878B2 (ja) 2007-07-06 2015-07-29 ルパン リミテッドLupin Limited リファキシミンの薬剤組成物
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009047801A1 (fr) 2007-10-10 2009-04-16 Lupin Limited Combinaisons thérapeutiques et compositions pour le traitement de troubles gastro-intestinaux
UA113275C2 (xx) 2008-02-25 2017-01-10 ζ-ФОРМА РИФАКСИМІНУ І ЇЇ ЗАСТОСУВАННЯ

Also Published As

Publication number Publication date
MD3653G8 (ro) 2016-08-31
AU2004287601B8 (en) 2009-03-05
DE602004019298D1 (de) 2009-03-19
EP1682556A2 (fr) 2006-07-26
HRP20060093B1 (hr) 2015-12-18
EP1557421A1 (fr) 2005-07-27
AU2004287601B2 (en) 2009-02-26
NO334950B1 (no) 2014-08-04
EP1676847A1 (fr) 2006-07-05
ATE421966T1 (de) 2009-02-15
SI1557421T1 (sl) 2007-08-31
KR100855084B1 (ko) 2008-08-29
RS20150292A1 (sr) 2015-10-30
DE04005541T1 (de) 2005-12-29
YU24804A (sh) 2006-08-17
CN1886408B (zh) 2010-06-09
CN101260115A (zh) 2008-09-10
DK1557421T3 (da) 2007-09-17
HK1092150A1 (en) 2007-02-02
MXPA06002644A (es) 2006-06-06
CN1886408A (zh) 2006-12-27
US7045620B2 (en) 2006-05-16
US20110160449A1 (en) 2011-06-30
JP2014177500A (ja) 2014-09-25
HRP20060093A2 (en) 2006-05-31
CY1108017T1 (el) 2013-09-04
MXPA04002353A (es) 2005-05-11
JP2011057698A (ja) 2011-03-24
AU2004287601A1 (en) 2005-05-19
HK1073657A1 (en) 2005-10-14
US20050101598A1 (en) 2005-05-12
AR043547A1 (es) 2005-08-03
PL1676847T3 (pl) 2009-07-31
RS54569B1 (sr) 2016-06-30
TWI285107B (en) 2007-08-11
CO5560083A1 (es) 2005-09-30
EP2208730A1 (fr) 2010-07-21
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
UA86384C2 (uk) 2009-04-27
DE602004006367D1 (de) 2007-06-21
EP1676847B1 (fr) 2009-01-28
CL2004000498A1 (es) 2005-03-11
EP1676848B1 (fr) 2009-01-28
CA2538546A1 (fr) 2005-05-19
RU2270200C2 (ru) 2006-02-20
KR20070113327A (ko) 2007-11-28
HK1092151A1 (en) 2007-02-02
ATE421965T1 (de) 2009-02-15
IL160798A0 (en) 2004-08-31
JP2005139161A (ja) 2005-06-02
ITMI20032144A1 (it) 2005-05-08
ZA200401948B (en) 2004-04-29
CA2538546C (fr) 2011-04-19
AR081992A2 (es) 2012-10-31
PT1676848E (pt) 2009-04-09
RS54568B1 (sr) 2016-06-30
TW200515913A (en) 2005-05-16
EP1557421B1 (fr) 2007-05-09
CN1613858A (zh) 2005-05-11
IL174271A (en) 2010-12-30
ES2244364T1 (es) 2005-12-16
EP1676848A1 (fr) 2006-07-05
JP2011046738A (ja) 2011-03-10
US7915275B2 (en) 2011-03-29
MA27069A1 (fr) 2004-12-20
ME00424B (fr) 2011-10-10
JP2007509904A (ja) 2007-04-19
PL1676848T3 (pl) 2009-07-31
WO2005044823A3 (fr) 2005-10-27
US20050272754A1 (en) 2005-12-08
MD3653F2 (en) 2008-07-31
KR20050043589A (ko) 2005-05-11
KR100883216B1 (ko) 2009-02-13
KR20070113326A (ko) 2007-11-28
ES2320161T3 (es) 2009-05-19
DE602004019296D1 (de) 2009-03-19
WO2005044823A2 (fr) 2005-05-19
US8173801B2 (en) 2012-05-08
CY1108909T1 (el) 2014-07-02
JP5635376B2 (ja) 2014-12-03
ES2320160T4 (es) 2011-03-09
DE602004006367T2 (de) 2007-09-06
KR100867751B1 (ko) 2008-11-10
RS20150291A1 (sr) 2015-10-30
AU2004200964A1 (en) 2005-05-26
NO20061110L (no) 2006-04-19
DE602004006367C5 (de) 2019-04-04
AR081991A2 (es) 2012-10-31
PT1676847E (pt) 2009-04-09
JP5199576B2 (ja) 2013-05-15
CY1108964T1 (el) 2014-07-02
TNSN06069A1 (en) 2007-10-03
MD20060080A (en) 2006-11-30
US20080132530A1 (en) 2008-06-05
ES2244364T3 (es) 2007-12-01
CN101260115B (zh) 2011-11-23
KR20060110737A (ko) 2006-10-25
PT1557421E (pt) 2007-07-31
US8404704B2 (en) 2013-03-26
CA2460384A1 (fr) 2005-05-07
SI1676847T1 (sl) 2009-06-30
DK1676848T3 (da) 2009-05-11
EP2210893A1 (fr) 2010-07-28
CN101260114B (zh) 2012-11-28
NZ531622A (en) 2004-10-29
TNSN04044A1 (en) 2006-06-01
ATE361927T1 (de) 2007-06-15
JO2470B1 (en) 2009-01-20
CN101260114A (zh) 2008-09-10
RU2004108953A (ru) 2005-10-27
SI1676848T1 (sl) 2009-06-30
BRPI0402382A (pt) 2005-06-28
IL174271A0 (en) 2006-08-01
BRPI0407149A8 (pt) 2019-01-15
PL1557421T3 (pl) 2007-08-31
RS20060168A (sr) 2008-09-29
BRPI0407149A (pt) 2006-02-07
US20120059023A1 (en) 2012-03-08
RS54571B1 (sr) 2016-06-30

Similar Documents

Publication Publication Date Title
DK1676848T3 (da) Polymorfe former af rifaximin som antibiotika
SE0302305D0 (sv) Novel Compounds
ECSP066436A (es) Compuestos heterociclicos fusionados
IS8108A (is) Ný efnasambönd
DK1605897T3 (da) Polyethelen-glycol-link-glp-1-forbindelser
DK1828167T3 (da) Acrylamidderivater som antibiotiske midler
DE602004018602D1 (de) Mikrospiegel
ATE463248T1 (de) Cephem-verbindungen
IS8228A (is) Ný asetídínefnasambönd
FI20030030A0 (fi) Uusia yhdisteitä
IS8089A (is) Efnasambönd
DK1667975T3 (da) En polymorf form for 3-phenylsulfonyl-8-piperazin-1-yl-quinolin
IS8292A (is) Ný efnasambönd
NO20031736D0 (no) Forbindelser
NO20055097D0 (no) Krystallinske N-formyl-hydroksylaminforbindelser
SE0303452D0 (sv) New compounds
DE602004028552D1 (de) Nockenwellenversteller
EP1793812A4 (fr) Compose antibiotique
EP1756034A4 (fr) Compose antibiotique
SE0300388D0 (sv) Novel compounds
SE0302667D0 (sv) Novel Compounds
SE0300118D0 (sv) Novel Compounds
FI20030095L (fi) Tasoituslana
SE0302369D0 (sv) New compounds
SE0302368D0 (sv) New compounds